基质金属蛋白酶与心血管疾病
Matrix metalloproteinases and cardiovascular diseases.
作者信息
Papazafiropoulou A, Tentolouris N
机构信息
Department of Propaedeutic Medicine, Laiko Hospital, Athens University Medical School, Athens, Greece.
出版信息
Hippokratia. 2009 Apr;13(2):76-82.
Abstract
Matrix metalloproteinases (MMPs) are extracellular enzymes that are important in many physiologic and pathologic processes. Their activity is regulated mainly by tissue inhibitors of metalloproteinases (TIMPs). MMPs expression is related with the classical cardiovascular risk factors as well as with inflammation. They play a central role in atherosclerosis, plaque formation, platelet aggregation, acute coronary syndrome, restenosis, aortic aneurysms and peripheral vascular disease. Many studies have shown that commonly prescribed antihypertensive medications, glitazones and statins may influence MMPs activity. The aim of the review is to present literature data on the role of MMPs and their inhibitors in cardiovascular disease.
摘要
基质金属蛋白酶（MMPs）是细胞外酶，在许多生理和病理过程中起重要作用。它们的活性主要受金属蛋白酶组织抑制剂（TIMPs）调节。MMPs的表达与经典心血管危险因素以及炎症有关。它们在动脉粥样硬化、斑块形成、血小板聚集、急性冠状动脉综合征、再狭窄、主动脉瘤和周围血管疾病中起核心作用。许多研究表明，常用的抗高血压药物、格列酮类药物和他汀类药物可能会影响MMPs的活性。本综述的目的是介绍关于MMPs及其抑制剂在心血管疾病中作用的文献数据。
相似文献
1
Matrix metalloproteinases and cardiovascular diseases.
Hippokratia. 2009 Apr;13(2):76-82.
2
Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases.
Curr Top Med Chem. 2012;12(10):1132-48. doi: 10.2174/1568026611208011132.
3
Matrix metalloproteinases and atherosclerosis.
Curr Atheroscler Rep. 2004 Mar;6(2):112-20. doi: 10.1007/s11883-004-0099-1.
4
Matrix metalloproteinases in peripheral vascular disease.
J Vasc Surg. 2007 Apr;45(4):849-57. doi: 10.1016/j.jvs.2006.09.066.
5
Matrix metalloproteinases and peripheral arterial disease.
Intern Emerg Med. 2010 Feb;5(1):13-25. doi: 10.1007/s11739-009-0283-y. Epub 2009 Jul 21.
6
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.
Biochem Pharmacol. 2008 Jan 15;75(2):346-59. doi: 10.1016/j.bcp.2007.07.004. Epub 2007 Jul 7.
7
Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability.
Int J Mol Sci. 2020 May 31;21(11):3946. doi: 10.3390/ijms21113946.
8
Characterization of the kallikrein-kinin system, metalloproteinases, and their tissue inhibitors in the in-stent restenosis after peripheral percutaneous angioplasty.
Ann Vasc Surg. 2014 May;28(4):1005-15. doi: 10.1016/j.avsg.2013.11.014. Epub 2014 Jan 16.
9
Granulocytes in coronary thrombus evolution after myocardial infarction--time-dependent changes in expression of matrix metalloproteinases.
Cardiovasc Pathol. 2016 Jan-Feb;25(1):40-6. doi: 10.1016/j.carpath.2015.09.007. Epub 2015 Oct 18.
10
Matrix metalloproteinases and diabetic vascular complications.
Angiology. 2005 Mar-Apr;56(2):173-89. doi: 10.1177/000331970505600208.
引用本文的文献
1
Profiling of proteases involved in SARS-CoV-2 pathogenesis in human saliva: Influence of age and gender.
J Genet Eng Biotechnol. 2025 Sep;23(3):100509. doi: 10.1016/j.jgeb.2025.100509. Epub 2025 Jun 17.
2
Metalloproteinases (MMPs) in hypertensive disorders: role, function, pharmacology, and potential strategies to mitigate pathophysiological changes.
Front Pharmacol. 2025 May 26;16:1559288. doi: 10.3389/fphar.2025.1559288. eCollection 2025.
3
Antiatherogenic and plaque stabilizing effects of saffron ethanolic extract in atherosclerotic rabbits.
BMC Complement Med Ther. 2025 May 23;25(1):187. doi: 10.1186/s12906-025-04927-6.
4
Exploring the Cardiovascular Benefits of Extra Virgin Olive Oil: Insights into Mechanisms and Therapeutic Potential.
Biomolecules. 2025 Feb 14;15(2):284. doi: 10.3390/biom15020284.
5
Network Pharmacology Approaches Used to Identify Therapeutic Molecules for Chronic Venous Disease Based on Potential miRNA Biomarkers.
J Xenobiot. 2024 Oct 15;14(4):1519-1540. doi: 10.3390/jox14040083.
6
Synergy Between NK Cells and Monocytes in Potentiating Cardiovascular Disease Risk in Severe COVID-19.
Arterioscler Thromb Vasc Biol. 2024 Oct;44(10):e243-e261. doi: 10.1161/ATVBAHA.124.321085. Epub 2024 Jul 11.
7
MMP-9-dependent proteolysis of the histone H3 N-terminal tail: a critical epigenetic step in driving oncogenic transcription and colon tumorigenesis.
Mol Oncol. 2024 Aug;18(8):2001-2019. doi: 10.1002/1878-0261.13652. Epub 2024 Apr 10.
8
The role of periostin in cardiac fibrosis.
Heart Fail Rev. 2024 Jan;29(1):191-206. doi: 10.1007/s10741-023-10361-y. Epub 2023 Oct 23.
9
The Effect of Calcineurin Inhibitors on MMPs Activity in Heart and Their Side Effects-A Review of Literature.
Int J Mol Sci. 2023 Jun 18;24(12):10291. doi: 10.3390/ijms241210291.
10
Residual risks and evolving atherosclerotic plaques.
Mol Cell Biochem. 2023 Dec;478(12):2629-2643. doi: 10.1007/s11010-023-04689-0. Epub 2023 Mar 10.
本文引用的文献
1
Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus.
J Diabetes Complications. 2010 Jan-Feb;24(1):20-7. doi: 10.1016/j.jdiacomp.2008.10.004. Epub 2008 Dec 5.
2
Nitric oxide and p38 MAP kinase mediate shear stress-dependent inhibition of MMP-2 production in microvascular endothelial cells.
J Cell Physiol. 2006 Jul;208(1):229-37. doi: 10.1002/jcp.20658.
3
The nitric oxide donor DETA-NONOate decreases matrix metalloproteinase-9 expression and activity in rat aortic smooth muscle and abdominal aortic explants.
Ann Vasc Surg. 2006 Jan;20(1):92-8. doi: 10.1007/s10016-005-9429-1.
4
Temporal exposure of cryptic collagen epitopes within ischemic muscle during hindlimb reperfusion.
Am J Pathol. 2005 Nov;167(5):1349-59. doi: 10.1016/S0002-9440(10)61222-9.
5
Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network.
Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1603-9. doi: 10.1161/01.ATV.0000171994.89106.ca. Epub 2005 May 26.
6
Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques.
Heart. 2005 Apr;91(4):521-5. doi: 10.1136/hrt.2003.012054.
7
Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women.
Int J Obes (Lond). 2005 May;29(5):498-501. doi: 10.1038/sj.ijo.0802897.
8
Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice.
Ann Surg. 2005 Jan;241(1):92-101. doi: 10.1097/01.sla.0000150258.36236.e0.
9
Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture.
Physiol Rev. 2005 Jan;85(1):1-31. doi: 10.1152/physrev.00048.2003.
10
Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity.
J Intern Med. 2005 Jan;257(1):110-6. doi: 10.1111/j.1365-2796.2004.01431.x.
Zotero 插件